Jefferies turns bullish on Renishaw and XP Power as chip cycle powers on

Jefferies upgraded Renishaw and XP Power to buy, citing expectations that a longer and stronger semiconductor cycle will drive additional earnings upgrades. The broker also raised Halma to hold from underperform and maintained its hold rating on Oxford Instruments. The note is positive for UK industrial companies with semiconductor exposure, particularly Renishaw and XP Power.

Analysis

The relevant differentiation is operating leverage to semiconductor capital-equipment recovery, not simply semiconductor exposure. RSW should have the cleaner upside if metrology demand broadens from leading-edge logic into industrial automation and machine-tool replacement, where incremental revenue can convert at high margins after a soft order period. XPP offers more asymmetric earnings torque because a utilization-driven recovery can improve factory absorption and working-capital conversion, but its smaller scale and customer concentration make the equity materially more volatile than RSW.

HLMA's rating change is more likely a valuation-risk reduction than a near-term earnings catalyst: its diversified safety, environmental and healthcare exposures dilute semiconductor upside, while its premium multiple leaves less room for a cyclical re-rating. OXIG remains the more direct alternative semiconductor-cycle expression, but its exposure to research and advanced-materials budgets introduces greater sensitivity to university, government and China-related spending than a pure wafer-fab-equipment recovery would imply.

Over the next 1-3 months, order intake, book-to-bill and management commentary on customer inventory normalization matter more than broker targets. A sustained improvement in foundry utilization and memory capex would support estimate revisions through the next two reporting periods; a renewed pause in China demand, delayed memory spending, or flat backlog conversion would quickly expose the thesis as a multiple-led move. The contrarian view is that consensus may be extrapolating a cycle recovery before UK industrial suppliers demonstrate revenue recognition: wait for independent order evidence rather than chase a one-day analyst-driven move.

Key Decisions for Investors

• Accumulate RSW on weakness over a 1-3 month horizon; use the next trading update as confirmation. Target a position only if management signals improving semiconductor order intake or book-to-bill above 1.0; exit/reassess on evidence of continued order declines or reduced full-year margin guidance.
• Use a RSW long / HLMA short pair for relative semiconductor-cycle exposure over 3-6 months. The trade isolates higher semiconductor operating leverage against a premium-rated diversified compounder; size modestly because HLMA's defensive end-markets can outperform if macro growth deteriorates.
• Treat XPP as a higher-beta satellite long rather than a core position. Enter only after evidence that revenue growth is translating into gross-margin recovery and cash conversion; the upside is earnings normalization over 6-12 months, while the key downside trigger is further working-capital build or customer-program slippage.
• Keep OXIG on watch rather than initiate solely on this signal. Upgrade the view only if semiconductor revenue momentum offsets research-market weakness; a recovery confined to leading-edge logic while academic or China demand remains soft would favor RSW over OXIG.